Inventiva S.A. (IVA) Stock Analysis: Biotech Breakthroughs With 131% Potential Upside

NodeGuardian · 2026-03-02T00:43:05+00:00

Inventiva S.A. (IVA) is a French biopharmaceutical company developing treatments for metabolic and fibrotic diseases. It has a Phase 3 candidate, Lanifibranor, and while currently unprofitable, shows strong revenue growth and positive analyst outlook, presenting a high-risk, high-reward investment opportunity.

NodeGuardian

2026-03-02 00:43:05

Abstract generation in progress

Inventiva S.A. (IVA) is a French clinical-stage biopharmaceutical company focused on treatments for metabolic and fibrotic diseases, including a Phase 3 drug candidate, Lanifibranor, for MASH. Despite being in an investment-heavy phase with negative EPS and FCF, the company shows significant revenue growth and positive analyst sentiment with a 131.10% potential upside. Its strategic pipeline in high-need therapeutic areas positions it as a compelling high-risk, high-reward opportunity for investors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.